4basebio (4BB)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 1,035.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 1,070.00
  • 52 Week Low: 500.00
  • Currency: UK Pounds
  • Shares Issued: 12.81m
  • Volume: 2,421
  • Market Cap: £132.53m

Losses to continue as 4basebio focuses on commercialisation

By Josh White

Date: Monday 09 May 2022

LONDON (ShareCast) - (Sharecast News) - Specialist DNA-focussed life sciences company 4basebio reported revenue of £0.34m in its final results on Monday, down from £0.46m year-on-year.
The AIM-traded firm said its gross profit was broadly stable for the year ended 31 December at £0.27m, although increased administration and research expenses led to its loss from operations widening to £3.53m from £0.62m.

Its total comprehensive loss for 2021 was £3.84m, compared to a £0.56m loss in 2020, while basic and diluted losses per share widened to 26p from 8p.

The company described 2021 as a "year of considerable progress" in its operational and strategic development.

4basebio said much of the year was focussed on the continuing validation and scaling of its DNA and non-viral delivery platform technologies.

As it entered the fourth quarter, the group said its attention moved toward commercialisation with the development of manufacturing suites near Cambridge.

The group said it invested "heavily" during the year, resulting in its much wider net loss.

With increasing activity, recruitment was said to have been a "key priority" both in the research and development and manufacturing teams, with the firm ending the year with a "strong growth" in headcount during the year and into the first quarter of 2022.

4basebio said it would continue to make a loss in 2022, and would rely on its cash resources, with the board noting that it also had access to a €25m (£21.37m) loan facility with its former parent company 2Invest.

"4basebio operates in a rapidly expanding and exciting market, where we view the commercial opportunity for our synthetic DNA and Hermes technologies with increasing confidence," said chief executive and scientific officer Dr Heikki Lanckriet.

"The significant progress made during to 2021 has led to our first DNA sales during 2022 and growing interest in our products from partners and prospective customers."

At 1100 BST, shares in 4basebio were down 9.09% at 500p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

4basebio Market Data

Currency UK Pounds
Share Price 1,035.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 1,070.00
52 Week Low 500.00
Volume 2,421
Shares Issued 12.81m
Market Cap £132.53m

4basebio Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
70.43% below the market average70.43% below the market average70.43% below the market average70.43% below the market average70.43% below the market average
28.3% below the sector average28.3% below the sector average28.3% below the sector average28.3% below the sector average28.3% below the sector average
Price Trend
97.59% above the market average97.59% above the market average97.59% above the market average97.59% above the market average97.59% above the market average
100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average100.00% above the sector average
Income Not Available
Growth
35.18% below the market average35.18% below the market average35.18% below the market average35.18% below the market average35.18% below the market average
51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average51.35% below the sector average

4basebio Dividends

No dividends found

Trades for 18-Apr-2024

Time Volume / Share Price
16:27 2,008 @ 1,070.00p
15:59 95 @ 1,048.00p
13:38 237 @ 1,050.00p
11:06 81 @ 1,069.00p

4basebio Key Personnel

CEO Heikki Lanckriet
CFO David John Roth

Top of Page